Carrizo Oil & Gas, Inc. (CRZO)’s President and CEO P Johnson Sold 36,257 Shares of the Company; CASI Pharmaceuticals, Inc. (CASI) Had 2 Bulls

Because of the stocks unload P Johnson made he is in the traders attention today. The President and CEO of Carrizo Oil & Gas Inc and an insider, sold 36,257 shares worth $537,782 U.S Dollars. The average price was $14.8 per share. He also sold 16,000 shares that are worth approx $269,344 USD in the last 30 days. The regulatory filing shows that P Johnson now has exactly 0.80% of the Texas-based company’s total market capitalization

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 5 analyst reports since October 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, August 14 by Maxim Group. The firm earned “Buy” rating on Thursday, October 29 by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, January 16. Maxim Group initiated it with “Buy” rating and $4 target in Thursday, September 22 report. See CASI Pharmaceuticals, Inc. (NASDAQ:CASI) latest ratings:

16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.5 Maintain

The stock increased 21.81% or $0.7 during the last trading session, reaching $3.91. About 863,799 shares traded or 285.31% up from the average. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since March 21, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $273.33 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Investors sentiment increased to 1.9 in Q3 2017. Its up 0.76, from 1.14 in 2017Q2. It increased, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported. Vanguard Gp Incorporated holds 358,972 shares. Manatuck Hill Prns Ltd Liability Com owns 15,090 shares. Bank Of America De reported 1,144 shares or 0% of all its holdings. Wellington Shields Lc, New York-based fund reported 725,348 shares. Moors & Cabot has 26,053 shares. Royal National Bank & Trust Of Canada holds 17,572 shares. California Employees Retirement Sys invested in 136,518 shares. Wells Fargo Com Mn owns 68 shares or 0% of their US portfolio. Wellington Shields & Limited Liability reported 489,984 shares. Next Financial Group owns 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 2 shares. Geode Mngmt Ltd Co holds 0% or 38,315 shares in its portfolio. Deutsche Bancshares Ag holds 0% or 21 shares. Morgan Stanley reported 1,157 shares. Jpmorgan Chase reported 9 shares stake. Blackrock accumulated 291,106 shares or 0% of the stock.

Carrizo Oil & Gas, Inc., together with its subsidiaries, engages in the exploration, development, and production of gas and oil primarily in the United States. The company has market cap of $1.21 billion. The firm holds interests in gas and oil plays, including Eagle Ford Shale in South Texas; the Delaware Basin in West Texas; the Niobrara Formation in Colorado; the Utica Shale in Ohio; and the Marcellus Shale in Pennsylvania. It has a 14.02 P/E ratio. As of December 31, 2015, it had proved gas and oil reserves of 200.2 million barrels of oil equivalent; and operated 667 gross productive gas and oil wells.

Among 30 analysts covering Carrizo Oil & Gas Inc. (NASDAQ:CRZO), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Carrizo Oil & Gas Inc. has $60 highest and $4 lowest target. $34.09’s average target is 129.41% above currents $14.86 stock price. Carrizo Oil & Gas Inc. had 120 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) earned “Buy” rating by Raymond James on Tuesday, December 12. RBC Capital Markets maintained Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) rating on Wednesday, December 20. RBC Capital Markets has “Buy” rating and $24.0 target. The firm has “Outperform” rating given on Friday, August 21 by Credit Suisse. BMO Capital Markets maintained it with “Outperform” rating and $38 target in Friday, September 4 report. The firm has “Neutral” rating by Goldman Sachs given on Tuesday, October 18. Jefferies maintained Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) on Thursday, November 16 with “Hold” rating. The company was upgraded on Tuesday, January 19 by KLR Group. The stock of Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) earned “Buy” rating by Robert W. Baird on Thursday, September 14. BMO Capital Markets maintained it with “Buy” rating and $23.0 target in Tuesday, November 14 report. The stock of Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) has “Buy” rating given on Tuesday, August 8 by Williams Capital Group.

The stock decreased 0.54% or $0.08 during the last trading session, reaching $14.86. About 2.82 million shares traded. Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) has declined 34.05% since March 21, 2017 and is downtrending. It has underperformed by 50.75% the S&P500.

Investors sentiment decreased to 1.13 in Q3 2017. Its down 0.36, from 1.49 in 2017Q2. It dropped, as 50 investors sold Carrizo Oil & Gas, Inc. shares while 37 reduced holdings. 34 funds opened positions while 96 raised stakes. 85.22 million shares or 8.23% more from 78.74 million shares in 2017Q2 were reported. Peak6 Ltd Partnership has 0% invested in Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) for 54,818 shares. Macquarie Grp Incorporated reported 0.05% in Carrizo Oil & Gas, Inc. (NASDAQ:CRZO). Tortoise Advsrs Ltd Liability Corp reported 296,480 shares. Voya Inv Limited Liability Com stated it has 2.02M shares. Vanguard Grp Inc invested 0.01% in Carrizo Oil & Gas, Inc. (NASDAQ:CRZO). Mutual Of America Management Lc holds 0.02% or 63,217 shares in its portfolio. Barclays Pcl reported 261,614 shares. Foundry Partners Limited Company reported 0.05% stake. Stevens Management Limited Partnership invested in 0.01% or 15,375 shares. Gradient Invests Lc has 0.04% invested in Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) for 32,682 shares. Panagora Asset Mngmt reported 1,400 shares stake. Legal General Grp Public Limited Co invested in 149,991 shares. Natixis accumulated 0% or 10,322 shares. State Street holds 0.01% of its portfolio in Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) for 4.88 million shares. Vr Advisory Svcs Ltd has 115,900 shares for 1.13% of their portfolio.

Since December 15, 2017, it had 0 buys, and 3 insider sales for $485,454 activity. Another trade for 8,000 shares valued at $148,592 was made by JOHNSON S P IV on Friday, December 15.